



Date: 07th January, 2026

To,
Corporate Relations Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Company Code: ACCPL

Dear Sir/ Madam,

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance to earlier intimation dated 28th October, 2025, we hereby inform you that the Company has received Adjudication Order from SEBI vide its order no. Order/AK/RK/2025-26/31951-31952 dated 07th January, 2026.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2025/25 dated 25th February, 2025, is enclosed herewith as Annexure.

You are requested to kindly take on your record.

Thanking You.

Yours truly,
For Accretion Pharmaceuticals Limited

Roshni Shah
Company Secretary and Compliance Officer

Annexure

Sr. No.	Particulars	Details
1.	Name of the Authority	Securities and Exchange Board of India (SEBI)
2.	Nature and details of the action(s) taken, initiated or order(s) passed.	Adjudication Order received from SEBI vide its order no. Order/AK/RK/2025-26/31951-31952 dated 07 th January, 2026 in respect of the imposition of a monetary penalty amounting Rs. 1,00,000/- under Section 15HB of SEBI Act.
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority.	07 th January, 2026
4.	Details of the violation(s) / contravention(s) committed or alleged to be committed.	SEBI observed that the management of the Company had made forward-looking projections during an investors' meet organized by the Company a day prior to the opening of the IPO. Accordingly, SEBI has issued an Adjudication Order for violation of Regulation 263 read with Clause 1, Clause 5 and Explanation I of Schedule IX of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and imposed a monetary penalty thereunder.
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible.	There is no impact on the financial, operational or other activities of the Company except only to the extent of the amount of penalty.